Client Resource, Health Markers
A single measurement. No blood draw. No scan. The mortality data behind it is more compelling than almost any standard blood marker.
Grip strength has been studied as a health marker for decades, but it is only in the last ten years that the scale and consistency of the evidence has become impossible to ignore. Across dozens of large prospective cohort studies covering millions of participants, grip strength is consistently one of the strongest predictors of all-cause mortality, cardiovascular mortality, cancer mortality, functional decline, cognitive decline, and hospitalisation, independent of age, body composition, physical activity, and most traditional risk factors.
The mechanism is not that grip strength itself causes or prevents disease. It predicts mortality because it is a proxy for overall musculoskeletal integrity, neuromuscular function, and systemic physiological reserve. A weak grip reflects a body that has lost meaningful functional capacity across multiple systems simultaneously. What makes it particularly useful is that it is cheap, fast, reproducible, and sensitive to change with training, making it both a diagnostic tool and a training outcome measure.
A 2022 systematic review and dose-response meta-analysis covering 48 prospective cohort studies and 3,135,473 participants found a significant inverse association between grip strength and all-cause, cardiovascular, and cancer mortality. The association was linear, there was no ceiling above which further strength provided no additional benefit. (López-Bueno et al., Ageing Research Reviews 2022)
The UK Biobank prospective cohort study (Celis-Morales et al., BMJ 2018) followed 502,293 adults and found that grip strength was inversely associated with all-cause, cardiovascular, and cancer mortality. Each 5 kg reduction in grip strength was associated with a 16% increase in all-cause mortality, a 17% increase in cardiovascular mortality, and a 17% increase in cancer mortality, after adjusting for age, sex, BMI, physical activity, smoking, and alcohol intake. The PURE study (Leong et al., Lancet 2015), following 139,691 adults across 17 countries, found that grip strength was more strongly associated with cardiovascular mortality than systolic blood pressure, one of the most established cardiovascular risk markers in clinical practice. Most GP appointments measure blood pressure and never measure grip strength.
Clinical significance: A 5 kg reduction in grip strength carries roughly the same mortality signal as a 10 mmHg increase in systolic blood pressure. The measurement takes 10 seconds with a dynamometer.
Grip strength does not predict mortality because hand strength itself is critical for survival. It predicts mortality because it reflects the overall integrity of the musculoskeletal system, neuromuscular efficiency, hormonal environment, nutritional status, and physiological reserve. Conditions that impair muscle quality, neuromuscular function, or metabolic health manifest in grip strength before they become clinically apparent elsewhere. The hand contains a dense concentration of musculature, tendon, nerve supply, and vascular network that together reflect systemic physiological status with unusual sensitivity. This is why grip strength adds independent predictive value on top of conventional risk factor models, it captures something those models miss.
The neuromuscular component: Grip strength reflects not just muscle mass but neural drive, motor unit recruitment, and the speed of neuromuscular signalling, all of which decline with age and disuse and all of which are independently associated with functional capacity and mortality.
The EWGSOP2 (European Working Group on Sarcopenia in Older People) uses grip strength as a primary diagnostic criterion for probable sarcopenia: below 27 kg for men and below 16 kg for women. The López-Bueno 2022 meta-analysis found mortality risk reduction was most pronounced and dose-dependent throughout the 26–50 kg range for men. For most working-age adults, the meaningful question is not whether you are above the clinical floor but where you sit within the functional range for your age and sex, and whether that is changing over time. Average grip strength in UK adults in their 40s is approximately 44–48 kg for men and 27–30 kg for women (dominant hand), declining approximately 1–2% per year without training.
At 70: Average values are roughly 35 kg for men and 22 kg for women. A 50-year-old who does not train may cross the EWGSOP2 threshold for probable sarcopenia before they retire.
A 2022 UK Biobank study (Duchowny et al., JAMA Network Open) following 190,406 participants found that lower grip strength was associated with higher risk of all-cause dementia, Alzheimer's disease, and vascular dementia, with a dose-response relationship. Each standard deviation reduction in grip strength was associated with a 9–10% increase in dementia risk after adjusting for age, sex, education, BMI, smoking, and multiple comorbidities. The mechanism is not fully understood but likely reflects shared pathophysiology, vascular health, inflammatory status, and neuromuscular integrity all influence both grip strength and cognitive resilience. This extends the relevance of tracking it beyond purely physical capacity.
The broader picture: Grip strength as a marker tracks physical capacity, cardiometabolic health, and cognitive reserve simultaneously. It is arguably the most information-dense single measurement available outside a clinical setting.
Grip strength improves with general resistance training, particularly compound pulling movements (rows, deadlifts, pull-ups) that load the forearm musculature under tension. Specific grip training, through farmer carries, dead hangs, thick-bar work, and plate pinches, produces faster improvements than general training alone. In older adults, resistance training interventions consistently show meaningful grip strength improvements within 8–12 weeks. The neural component of grip strength responds quickly to appropriate stimulus, meaning early improvements often reflect neural adaptation before significant hypertrophy has occurred.
Practical protocol: Incorporate farmer carries (heavy, bilateral, 30–40 metres), dead hangs (2–3 sets of maximum duration), and plate pinches 2–3 times weekly. These provide the eccentric and isometric loading most effective for grip development alongside general compound pulling work.
Grip strength is typically measured bilaterally, and asymmetry between dominant and non-dominant hands provides additional information. A symmetry ratio below 0.90 (non-dominant less than 90% of dominant) is generally considered clinically meaningful. Significant asymmetry is associated with increased fall risk, altered movement mechanics, and in some populations with greater functional decline than low bilateral grip alone. Following orthopaedic injury, joint replacement, neurological events, or prolonged immobilisation, grip asymmetry often persists for years without targeted rehabilitation.
NTCZ relevance: The Benchmark measures grip strength bilaterally using the VALD DynaMo dynamometer, recording peak force and left-right asymmetry alongside leg extension and hip abduction. This provides both absolute values against reference ranges and the asymmetry picture that standard gym assessments miss.
Without consistent resistance training, a 40-year-old can expect to lose roughly 25–30% of their grip strength by age 70, potentially enough to cross clinical thresholds that predict hospitalisation and loss of independence. Consistent resistance training can maintain or improve grip strength well into the seventh and eighth decades. The Benchmark measures it at a point in time; re-testing annually provides the data to confirm whether training is maintaining or improving the physical quality that carries this level of prognostic significance.
Tracking value: A grip strength measurement today compared with one taken 12 months later, after a year of consistent training, is one of the most direct objective measures of whether your programme is working at the physiological level that matters for longevity.
Grip strength is a proxy, not a perfect marker. But it is a proxy for something real, overall musculoskeletal integrity, neuromuscular function, and physiological reserve, and the scale of the mortality data behind it is larger and more consistent than most markers that receive far more clinical attention. A sub-30 kg grip strength in a man in his 40s or 50s is a signal worth taking seriously, in the same way an elevated resting heart rate or rising waist-to-height ratio is.
The practical response is consistent resistance training with specific attention to loaded grip work. Measure it. Train it. Retest it annually. The data on what happens to people who do not is clear.
Book The Benchmark →López-Bueno R et al., Thresholds of handgrip strength for all-cause, cancer, and cardiovascular mortality: a systematic review with dose-response meta-analysis. Ageing Res Rev 2022;82:101778. 48 studies, 3,135,473 participants.
Celis-Morales CA et al., Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ 2018;361:k1651. 502,293 adults. Each 5 kg reduction = 16% increased mortality.
Leong DP et al. (PURE study), Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet 2015;386(9990):266–273. 139,691 participants across 17 countries. Grip strength stronger CVD predictor than blood pressure.
Duchowny KA et al., Associations between handgrip strength and dementia risk, cognition, and neuroimaging outcomes in the UK Biobank cohort study. JAMA Netw Open 2022;5(6):e2218314. 190,406 participants. Dementia risk.
Cruz-Jentoft AJ et al. (EWGSOP2), Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31. Clinical diagnostic thresholds.